New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
07:55 EDTVTLVital Therapies price target raised to $35 from $20 at Canaccord
Canaccord raised its price target on Vital Therapies to $35 from $20 based on the probability of the success of its Alcohol Induced Liver Disease drug and its substantial market opportunity. Canaccord maintains its Buy rating on Vital Therapies.
News For VTL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
06:59 EDTVTLVital Therapies initiated with a Buy at SunTrust
Subscribe for More Information
December 11, 2014
10:13 EDTVTLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:24 EDTVTLVital Therapies upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
06:19 EDTVTLVital Therapies upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
December 8, 2014
08:05 EDTVTLVital Therapies announces first subject enrolled in VTI-210
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use